Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 11 of 11 for:    "Arcus Biosciences, Inc." [Exact]

A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03628677
Recruitment Status : Recruiting
First Posted : August 14, 2018
Last Update Posted : September 4, 2020
Sponsor:
Information provided by (Responsible Party):
Arcus Biosciences, Inc.

Brief Summary:
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with zimberelimab (AB122) in participants with advanced solid malignancies.

Condition or disease Intervention/treatment Phase
Solid Tumor, Unspecified, Adult Drug: AB154 Drug: Zimberelimab Phase 1

Detailed Description:
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of AB154 as monotherapy and in combination with zimberelimab in participants with advanced solid malignancies. In this dose escalation study, participants will receive AB154 administered intravenously as monotherapy or in combination with zimberelimab. Treatment will continue until progressive disease, unacceptable toxicity, withdrawal of consent, or other reasons for study drug discontinuation occurs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Dose Escalation Design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Actual Study Start Date : September 12, 2018
Estimated Primary Completion Date : July 7, 2021
Estimated Study Completion Date : November 10, 2021

Arm Intervention/treatment
Experimental: AB154 Monotherapy
Varying Doses of AB154 Monotherapy
Drug: AB154
AB154 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Experimental: AB154 + zimberelimab Q2W Combination Therapy
Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
Drug: AB154
AB154 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Name: AB122

Experimental: AB154 + zimberelimab Q3W Combination Therapy
Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
Drug: AB154
AB154 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Name: AB122

Experimental: AB154 + zimberelimab Q4W Combination Therapy
Varying Doses of AB154 in Combination With Varying Doses of zimberelimab
Drug: AB154
AB154 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting human TIGIT

Drug: Zimberelimab
Zimbererlimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody targeting human PD-1
Other Name: AB122




Primary Outcome Measures :
  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0 [ Time Frame: From First Dose Date to 6 Months After Last Dose ]
    Number of Participants Treated with AB154 or AB154 in Combination with AB122 with Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0


Secondary Outcome Measures :
  1. AB154 Peak Plasma Concentration (Cmax) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Peak Plasma Concentration (Cmax) of AB154

  2. Zimberelimab Peak Plasma Concentration (Cmax) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Peak Plasma Concentration (Cmax) of zimberelimab

  3. AB154 Time of Peak Concentration (Tmax) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Time of Peak Concentration (Tmax) of AB154

  4. Zimberelimab Time of Peak Concentration (Tmax) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Time of Peak Concentration (Tmax) of zimberelimab

  5. AB154 Area Under the Plasma Concentration Versus Time Curve (AUC) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Area Under the Plasma Concentration Versus Time Curve (AUC) of AB154

  6. Zimberelimab Area Under the Plasma Concentration Versus Time Curve (AUC) [ Time Frame: Day 1 (sequential), Day 2, Day 3, Day 4, Day 8, Day 15, Day 22, Day 29 (sequential), Day 30, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 113, Day 141 and 30 Days After Last Dose, up to 52 weeks ]
    Area Under the Plasma Concentration Versus Time Curve (AUC) of zimberelimab

  7. AB154 Receptor Occupancy [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  8. AB154 Immunophenotyping [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  9. AB154 Gene Expression [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  10. AB154 Cytokines [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  11. Zimberelimab Receptor Occupancy [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Receptor Occupancy May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  12. Zimberelimab Immunophenotyping [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Immunophenotyping May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  13. Zimberelimab Cytokines [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, and 30 Days After Last Dose, up to 52 weeks ]
    Cytokines May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  14. Zimberelimab Gene Expression [ Time Frame: Day 1, Day 3, Day 8, Day 15, Day 22, Day 29, Day 31, Day 36, Day 43, Day 57, Day 64, Day 85, Day 106, Day 141, and 30 Days After Last Dose, up to 52 weeks ]
    Gene Expression May be Summarized by Dose Group and Subject Over Time by Aggregating Data From Exploratory Biomarkers Collected From Peripheral Blood Samples

  15. Immunogenicity Indicators: Anti-Drug Antibodies (ADA) [ Time Frame: Day 1, Day 15, Day 29, Day 43, Day 57, Day 85 and 30 Days After Last Dose, up to 52 weeks ]
    Number of Participants who Develop Antidrug Antibodies to AB154 and/or AB122

  16. Overall Response Rate [ Time Frame: First Dose Date to Progression or Last Tumor Assessment, up to 1 year ]
    Number of Participants with Complete or Partial Response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.1

  17. Duration of Response [ Time Frame: Start Date of Response to First Progression/Death, up to 1 year ]
    Time at Which Response Criteria are Met for Complete Response or Partial Response (Whichever Occurs First) Until the First Date of Recurrence, Progression or Death per RECIST v1.1

  18. Disease Control Rate [ Time Frame: First Dose Date to First Progression/Death, up to 1 year ]
    Number of Participants with Complete Response, Partial Response, or Stable Disease for Greater Than 6 Months per RECIST v1.1

  19. Progression Free Survival [ Time Frame: First Dose Date to First Progression/Death, up to 1 year ]
    Number of Participants Without Disease Progression per RECIST v1.1

  20. Overall Survival [ Time Frame: First Dose Date to Date of Death, up to 1 year ]
    Overall Survival Rate, Defined as Time Between First Dose Date and Date of Death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Capable of giving signed informed consent
  2. Male or female participants ≥ 18 years of age at the time of screening
  3. Negative serum pregnancy test at screening and prior to dosing on Cycle 1 Day 1; negative serum or urine pregnancy test on the first day of each subsequent treatment period
  4. Participants with any pathologically confirmed solid tumor type for which no standard of care therapy exists
  5. Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. The measurable lesion must be outside of a radiation field if the participant received prior radiation
  6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  7. Confirmation that an archival tissue sample is available and ≤ 6 months old; if not, a new biopsy of a tumor must be obtained
  8. Prior chemotherapy, targeted small-molecule therapy, immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) or biologic agents must have been discontinued at least 4 weeks before investigational product administration, and all AEs have either returned to baseline or ≤ Grade 1
  9. Immunosuppressive doses of systemic medications, such as corticosteroids or absorbed topical corticosteroids (doses > 10 mg/day prednisone or equivalent) must be discontinued at least 2 weeks (14 days) before investigational product administration. Physiologic doses of corticosteroids ≤ 10 mg/day of prednisone or its equivalent may be permitted
  10. Prior surgery that required general anesthesia or other major surgery as defined by the Investigator must be completed at least 4 weeks before investigational product administration
  11. Negative tests for hepatitis B surface antigen, hepatitis C virus antibody (or hepatitis C qualitative ribonucleic acid [RNA; qualitative]), and human immunodeficiency virus (HIV)-1 and HIV-2 antibody at screening
  12. Adequate organ and marrow function

Exclusion Criteria:

  1. Use of any live vaccines against infectious diseases (eg, influenza, varicella) within 4 weeks (28 days) of initiation of investigational product
  2. Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational product hazardous (eg, interstitial lung disease, active infections requiring antibiotics, recent hospitalization with unresolved symptoms)
  3. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
  4. Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the pre-screening or screening visit through 100 days after the last dose of AB154 as monotherapy and in combination with AB122.
  5. Participants who require a Legally Authorized Representative (LAR) to provide informed consent on their behalf.
  6. Any active autoimmune disease or a documented history of autoimmune disease or history of a syndrome that required systemic steroids or immunosuppressive medications, except for vitiligo or resolved childhood asthma/atopy. Participants with asthma who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study
  7. Prior malignancy active within the previous year except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
  8. Has had prior chemotherapy, targeted small-molecule therapy, or radiation therapy within 2 weeks prior to Day 1 or has not recovered from AEs due to a previously administered agent
  9. Use of other investigational drugs within 28 days or at least 5 half-lives before investigational product administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03628677


Contacts
Layout table for location contacts
Contact: Medical Director 510-694-6220 ClinicalTrialInquiry@arcusbio.com

Locations
Layout table for location information
United States, California
The Angeles Clinic and Research Institute Recruiting
Los Angeles, California, United States, 90025
Contact: Michele Azada    310-231-2182    mazada@theangelesclinic.org   
Principal Investigator: Ani Balmanoukian, MD         
United States, North Carolina
Carolina BioOncology Institute Recruiting
Huntersville, North Carolina, United States, 28078
Contact: Ashley McClain    980-441-1021    amcclain@carolinabiooncology.org   
Principal Investigator: John Powderly, MD         
United States, Texas
MD Anderson Cancer Center Active, not recruiting
Houston, Texas, United States, 77030
START Recruiting
San Antonio, Texas, United States, 78229
Contact: Carrie Eckhart    210-593-2574    Carrie.Eckart@startsa.com   
Principal Investigator: Amita Patnaik, MD         
United States, Washington
Medical Oncology Associates, PS (dba Summit Cancer Centers) Recruiting
Spokane, Washington, United States, 99208
Contact: Monika Chaudhry    509-462-2273    chaudhrym@nwrm.com   
Principal Investigator: Arvind Chaudhry, MD         
Australia, New South Wales
Albury, Australia Completed
Albury, New South Wales, Australia, 2640
Principal Investigator Completed
Camperdown, New South Wales, Australia, 2050
The Kinghorn Cancer Centre Recruiting
Darlinghurst, New South Wales, Australia, 2010
Contact: Robert Kent       robert.kent@svha.org.au   
Principal Investigator: Amy Prawira, MD         
Scientia Clinical Research Recruiting
Randwick, New South Wales, Australia, 2031
Contact: Justin Sim       justin.sim@scientiaclinicalresearch.com.au   
Principal Investigator: James Kuo, MD         
Principal Investigator Completed
Tweed Heads, New South Wales, Australia, 2480
Australia, Queensland
Principal Investigator Completed
South Brisbane, Queensland, Australia, 4101
Australia, Victoria
Olivia Newton-John Cancer Research Institute Completed
Heidelberg, Victoria, Australia, 3084
Sponsors and Collaborators
Arcus Biosciences, Inc.
Investigators
Layout table for investigator information
Study Director: Medical Director Arcus Biosciences, Inc.
Layout table for additonal information
Responsible Party: Arcus Biosciences, Inc.
ClinicalTrials.gov Identifier: NCT03628677    
Other Study ID Numbers: AB154CSP0001
First Posted: August 14, 2018    Key Record Dates
Last Update Posted: September 4, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms